中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

133 records (took 0.036 seconds)

    METHOD FOR ORAL ADMINISTRATION OF BUSPIRONE
    1.
    发明申请
    METHOD FOR ORAL ADMINISTRATION OF BUSPIRONE 审中-公开
    伯普林酮口服药物治疗方法

    公开(公告)号：WO1998024411A2

    公开(公告)日：1998-06-11

    申请号：PCT/US1997019929

    申请日：1997-11-06

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  SALAZAR, Daniel, E.

    IPC: A61K09/00

    CPC classification number: A61K31/505 ,  A61K31/495 ,  A61K2300/00

    Abstract: An improved method for orally administering buspirone to a human subject wherein the bioavailability of buspirone is increased and its elimination, metabolite formation, and variability of these pharmacokinetic parameters is decreased, the improvement comprises the concurrent administration of a sufficient amount of nefazodone to effect these pharmacokinetic changes for orally administered buspirone.

    Abstract translation: 一种改进的方法用于将人螺旋体口服给予人类对象，其中丁螺环酮的生物利用度增加，并且其消除，代谢物形成和这些药代动力学参数的变异性降低，改善包括同时给予足量的奈法唑酮以实现这些药代动力学 口服丁螺环酮的变化。

    DEVICES AND METHODS FOR APPLYING A MIXTURE OF TWO OR MORE LIQUID COMPONENTS TO FORM A BIOMATERIAL
    2.
    发明申请
    DEVICES AND METHODS FOR APPLYING A MIXTURE OF TWO OR MORE LIQUID COMPONENTS TO FORM A BIOMATERIAL 审中-公开
    用于将两种或更多液体组分的混合物用于形成生物体的装置和方法

    公开(公告)号：WO1998020931A1

    公开(公告)日：1998-05-22

    申请号：PCT/US1997020653

    申请日：1997-11-14

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  HOLM, Niels, Erik ,  LINNEBJERG, Steven ,  CORNWELL, Richard

    IPC: A61M31/00

    CPC classification number: A61B17/00491 ,  A61B2017/00495 ,  A61M35/00 ,  B05B7/08 ,  B05B7/0876

    Abstract: Novel methods and devices which provide enhanced mixing, and application of two liquid components to form a biomaterial with minimized aerosols, are achieved using airflow rates below about 1.25 liters/minute in combination with a ratio of airflow to total liquid flow of from about 150:1 up to about 1500:1. Preferably the airflow is below about 1 liter/minute, and the ratio of airflow to total liquid flow is from about 200:1 to about 1200:1. The parameters are ideally suited for the spray application of components which form a surgical sealant, e.g., a fibrin sealant. Also a part of the present invention is novel application methods for biomaterial, e.g., surgical sealant, components at liquid flows below 1.9 ml/minute, novel methods involving the mixing of such components on the exit surface of a spray tip (14), or nozzle, novel spray tips (14), biomaterial applicators, and methods for making such applicators.

    Abstract translation: 使用低于约1.25升/分钟的气流速率结合两个液体组分以形成具有最小气溶胶的生物材料的新方法和装置，结合气流与总液体流量的比例为约150:1， 1到1500：1。 优选地，气流低于约1升/分钟，并且气流与总液体流量的比率为约200:1至约1200:1。 这些参数非常适用于喷雾施用形成外科密封剂的组分，例如纤维蛋白封闭剂。 本发明的另一部分是用于生物材料的新型应用方法，例如手术密封剂，液体流速低于1.9ml /分钟的组分，涉及在喷嘴（14）的出口表面上混合这些组分的新方法，或 喷嘴，新型喷嘴（14），生物材料施加器以及制造这种涂敷器的方法。

    IMPROVED WOUND DRESSING
    3.
    发明申请
    IMPROVED WOUND DRESSING 审中-公开
    改进的连衣裙

    公开(公告)号：WO1998012996A1

    公开(公告)日：1998-04-02

    申请号：PCT/US1997017140

    申请日：1997-09-22

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  KADASH, Marjory, A. ,  MARSH, Thomas, A. ,  SMITH, Salina

    IPC: A61F05/00

    CPC classification number: A61L15/46 ,  A61F13/023 ,  A61F13/42 ,  A61L15/42 ,  A61L15/60 ,  A61L2300/404 ,  A61L2300/412

    Abstract: An improved wound dressing (10) is provided which comprises a backing layer (20) bearing a reference marking (25), a hydrocolloid layer (30), and a release layer (40). The hydrocolloid (30) swells in use. This swelling can be seen or felt through the backing layer (20). When the swelling extends to or beyond the reference marking (25), the dressing (10) should be changed to prevent leaking. Thus, the dressing (10) can be left in place for as long as possible, but not so long as to damage the underlying skin.

    Abstract translation: 提供了一种改进的伤口敷料（10），其包括具有参考标记（25），水胶体层（30）和脱模层（40）的背衬层（20）。 水胶体（30）在使用中膨胀。 可以通过背衬层（20）看到或感觉到这种膨胀。 当膨胀延伸至或超过参考标记（25）时，应改变敷料（10）以防止泄漏。 因此，敷料（10）可以留在适当的位置，尽可能长，但不会损坏下面的皮肤。

    SOLVENT EXTRACTION OF 3-HYDROXYMETHYLCEPHALOSPORINS
    6.
    发明申请
    SOLVENT EXTRACTION OF 3-HYDROXYMETHYLCEPHALOSPORINS 审中-公开
    溶剂萃取3-羟基甲基硬脂酰胺

    公开(公告)号：WO1998004565A1

    公开(公告)日：1998-02-05

    申请号：PCT/US1997012194

    申请日：1997-07-14

    Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  LIM, Gary, M., F. ,  ROUBIE, John, M. ,  AUDIA, Vicki, H.

    Inventor： BRISTOL-MYERS SQUIBB COMPANY

    IPC: C07D501/60

    CPC classification number: C07D501/00

    Abstract: The cephalosporin intermediate, desacetyl 7-glutaryl ACA, is obtained in the form of a concentrated aqueous solution from an aqueous solution containing said intermediate in less concentrated form by solvent extraction using cyclohexanone followed by back-extraction into water. The concentrated aqueous solution of intermediate is in a form which can be used for economical production of 7-ACA using known procedures.

    Abstract translation: 头孢菌素中间体脱乙酰基7-戊二酸ACA以浓缩水溶液的形式从含有较低浓度形式的中间体的水溶液形式通过溶剂萃取使用环己酮，然后反萃取到水中而获得。 中间体的浓缩水溶液是可以用于使用已知方法经济地生产7-ACA的形式。

    DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS
    7.
    发明申请
    DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS 审中-公开
    二苯醚作为钾通道调节剂

    公开(公告)号：WO1998004135A1

    公开(公告)日：1998-02-05

    申请号：PCT/US1997014352

    申请日：1997-07-30

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  ROMINE, Jeffrey, L. ,  MARTIN, Scott, W. ,  HEWAWASAM, Piyasena ,  MEANWELL, Nicholas, A. ,  GRIBKOFF, Valentin, K. ,  STARRETT, John, E., Jr.

    IPC: A01N43/653

    CPC classification number: C07D263/58 ,  C07D233/64 ,  C07D233/70 ,  C07D233/76 ,  C07D235/12 ,  C07D249/12 ,  C07D249/14 ,  C07D271/113 ,  C07D413/10

    Abstract: Novel compounds of formula (1) are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels, wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R , R and R each are independently selected from hydrogen, halogen, OH, CF3, NO2, or (a); provided R is not hydrogen; and when R and R are hydrogen, R may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; R and R each are independently selected form hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and R and R each are independently hydrogen; C1-4 alkyl; or R and R , taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.

    Abstract translation: 式（1）的新型化合物可用于治疗对大电导钙激活钾通道的开放物起反应的病症，其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2或（a）; 条件是R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分， 基; R d和R e各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; 和R f和R g各自独立地为氢; C 1-4烷基; 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。

    METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS
    9.
    发明申请
    METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS 审中-公开
    用于治疗具有使用MTP抑制剂的高LDL要求的肿瘤的方法

    公开(公告)号：WO1998003174A1

    公开(公告)日：1998-01-29

    申请号：PCT/US1997012158

    申请日：1997-07-14

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  FIRESTONE, Raymond, A.

    IPC: A61K31/445

    CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/4468 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454

    Abstract: A method is provided for treating hematologic tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an MTP inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematologic tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.

    Abstract translation: 提供了一种用于治疗血液肿瘤和实体瘤的方法，包括某些类型的白血病和转移性肿瘤，具有高LDL需求，使用脱脂剂如MTP抑制剂以显着降低LDL血液水平。 此外，提供了一种用于治疗具有高LDL要求的上述类型的肿瘤的方法，特别是血液学肿瘤例如某些白血病，使用去脂化合物基本上除去天然的LDL，然后给予重组的LDL中携带的细胞毒性剂。

Patent Agency Ranking